Oppenheimer Reaffirms Outperform Rating for Vor Biopharma (NYSE:VOR)

Vor Biopharma (NYSE:VOR - Get Free Report)'s stock had its "outperform" rating restated by research analysts at Oppenheimer in a report released on Friday,Benzinga reports. They presently have a $8.00 price target on the stock.

VOR has been the subject of several other reports. HC Wainwright cut their price objective on Vor Biopharma from $17.50 to $13.00 and set a "buy" rating for the company in a report on Friday. Stifel Nicolaus reduced their price target on Vor Biopharma from $12.00 to $5.00 and set a "buy" rating for the company in a report on Friday. JMP Securities reissued a "market outperform" rating and issued a $12.00 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. Finally, Wedbush reaffirmed an "outperform" rating and set a $7.00 price objective on shares of Vor Biopharma in a research report on Thursday, March 20th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $8.86.

Vor Biopharma Price Performance

Vor Biopharma stock traded down $0.04 during trading hours on Friday, hitting $0.85. The company had a trading volume of 166,281 shares, compared to its average volume of 591,618. The firm's fifty day moving average is $1.20 and its 200-day moving average is $1.01. The firm has a market capitalization of $58.19 million, a P/E ratio of -0.51 and a beta of -0.40. Vor Biopharma has a fifty-two week low of $0.63 and a fifty-two week high of $2.43.

Remove Ads

Institutional Investors Weigh In On Vor Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. RA Capital Management L.P. grew its holdings in Vor Biopharma by 74.3% during the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock valued at $44,007,000 after purchasing an additional 16,897,159 shares during the last quarter. Lynx1 Capital Management LP bought a new stake in shares of Vor Biopharma during the 4th quarter worth $707,000. Trustees of Columbia University in the City of New York acquired a new position in Vor Biopharma in the 4th quarter valued at $102,000. XTX Topco Ltd bought a new position in Vor Biopharma in the 4th quarter worth $80,000. Finally, Virtu Financial LLC acquired a new position in Vor Biopharma during the 4th quarter worth $60,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.